Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
06996 ANTENGENE-B
4.540
+0.180+4.13%
YOY
Do not show
Hide blank lines
(Q6)2022/06/30(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31
Turnover
-- 53.96M -- 28.77M -- -- -- --
Operating income
53.96M 28.77M
Cost of sales
-- -8.71M -- -4.58M -- -- -- --
Operating expenses
-8.71M -4.58M
Gross profit
45.25M 24.19M
Selling expenses
-68,367.42% -90.38M -14,832.09% -67.94M -- -132K -1,795.83% -455K
Administrative expenses
-9.38% -85.88M -9.88% -169.46M -14.31% -78.51M -291.93% -154.22M
Research and development expenses
-32.57% -179.41M -16.50% -405.03M 20.34% -135.33M -200.24% -347.66M
Special items of operating profit
1,003.79% 166.32M 98.49% -36.59M 93.84% -18.4M -1,345.63% -2.43B
Operating profit
37.99% -144.1M 77.63% -654.83M 56.75% -232.38M -806.60% -2.93B
Financing cost
42.37% -355K 32.36% -698K -37.50% -616K -23.44% -1.03M
Earning before tax
38.00% -144.45M 77.62% -655.53M 56.67% -233M -804.58% -2.93B
After-tax profit from continuing operations
38.00% -144.45M 77.62% -655.53M 56.67% -233M -804.58% -2.93B
Earning after tax
38.00% -144.45M 77.62% -655.53M 56.67% -233M -804.58% -2.93B
Profit attributable to shareholders
38.00% -144.45M 77.62% -655.53M 56.67% -233M -804.58% -2.93B
Basic earnings per share
37.84% -0.23 90.99% -1.05 85.66% -0.37 -647.44% -11.66
Diluted earnings per share
37.84% -0.23 90.99% -1.05 85.66% -0.37 -647.44% -11.66
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASIASIASIAS
Audit Opinions
--Unqualified Opinion--Unqualified Opinion
Auditor
--Ernst & Young accounting firm--Ernst & Young accounting firm

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Deqi Pharmaceutical is a leading biopharmaceutical company focused on innovative antineoplastic drugs. Our uniqueness comes from our industry-leading R & D capabilities and differentiated strategic approaches to developing new antineoplastic therapies. Our vision is to discover, develop and commercialize the world's first, unique and / or best-of-class therapy, treat patients without borders and improve their living standards. Through the effective use of resources, outstanding ability in target selection and differentiated R & D strategy, Deqi Pharmaceuticals has established a strong and highly coordinated R & D pipeline of 12 products, including two late clinical assets and four early clinical assets. In addition, we are developing six pre-clinical R & D drugs that focus on innovative targets or mechanisms and have the potential to be number one in their class to address huge unmet medical needs. Moreover, these drugs target the key pathways of carcinogenesis and have the potential to be combined with each other. Since its inception, we have established a solid R & D framework in the Asia-Pacific region and have a pan-Asia-Pacific clinical R & D capability. At this stage, we are establishing a commercialization team in the Asia-Pacific region to support the recent product launch, which is made up of multinational leaders with rich business experience and experienced practitioners who have in-depth knowledge of the developments in each local market.
CEO: Jianming Mei
Market: Hong Kong motherboard
Listing Date: 11/20/2020
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist